198 related articles for article (PubMed ID: 16203807)
1. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
DeNardo SJ; DeNardo GL; Miers LA; Natarajan A; Foreman AR; Gruettner C; Adamson GN; Ivkov R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7087s-7092s. PubMed ID: 16203807
[TBL] [Abstract][Full Text] [Related]
2. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
DeNardo SJ; DeNardo GL; Natarajan A; Miers LA; Foreman AR; Gruettner C; Adamson GN; Ivkov R
J Nucl Med; 2007 Mar; 48(3):437-44. PubMed ID: 17332622
[TBL] [Abstract][Full Text] [Related]
3. NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.
Natarajan A; Gruettner C; Ivkov R; DeNardo GL; Mirick G; Yuan A; Foreman A; DeNardo SJ
Bioconjug Chem; 2008 Jun; 19(6):1211-8. PubMed ID: 18517234
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
[TBL] [Abstract][Full Text] [Related]
5. Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells.
Lehmann J; Natarajan A; Denardo GL; Ivkov R; Foreman AR; Catapano C; Mirick G; Quang T; Gruettner C; Denardo SJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):265-71. PubMed ID: 18454696
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ
Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
[TBL] [Abstract][Full Text] [Related]
7. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Miers L; Lamborn K; Yuan A; Richman C; Natarajan A; DeNardo S; DeNardo G
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7158s-7163s. PubMed ID: 16203816
[TBL] [Abstract][Full Text] [Related]
8. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
DeNardo SJ; Gumerlock PH; Winthrop MD; Mack PC; Chi SG; Lamborn KR; Shen S; Miers LA; deVere White RW; DeNardo GL
Cancer Res; 1995 Dec; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
[TBL] [Abstract][Full Text] [Related]
10. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
DeNardo SJ; Kukis DL; Kroger LA; O'Donnell RT; Lamborn KR; Miers LA; DeNardo DG; Meares CF; DeNardo GL
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4000-4. PubMed ID: 9108094
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
[TBL] [Abstract][Full Text] [Related]
12. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
Natarajan A; Xiong CY; Gruettner C; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 2008 Feb; 23(1):82-91. PubMed ID: 18298332
[TBL] [Abstract][Full Text] [Related]
13. The biologic window for chimeric L6 radioimmunotherapy.
DeNardo SJ; Mirick GR; Kroger LA; O'Grady LF; Erickson KL; Yuan A; Lamborn KR; Hellstrom I; Hellstrom KE; DeNardo GL
Cancer; 1994 Feb; 73(3 Suppl):1023-32. PubMed ID: 8306244
[TBL] [Abstract][Full Text] [Related]
14. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer.
Ivkov R; DeNardo SJ; Daum W; Foreman AR; Goldstein RC; Nemkov VS; DeNardo GL
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7093s-7103s. PubMed ID: 16203808
[TBL] [Abstract][Full Text] [Related]
15. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
DeNardo SJ; Burke PA; Leigh BR; O'Donnell RT; Miers LA; Kroger LA; Goodman SL; Matzku S; Jonczyk A; Lamborn KR; DeNardo GL
Cancer Biother Radiopharm; 2000 Feb; 15(1):71-9. PubMed ID: 10740655
[TBL] [Abstract][Full Text] [Related]
16. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
[TBL] [Abstract][Full Text] [Related]
17. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
19. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Denardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
Anticancer Res; 1998; 18(6A):4011-8. PubMed ID: 9891439
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
